nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.09.2009 | Mini Review

Temozolomide in malignant gliomas: current use and future targets

verfasst von: J. Lee Villano, Tara E. Seery, Linda R. Bressler

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ—mechanism of action, scheduling and strategies for overcoming resistance.

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRef

CBTRUS (2008) Statistical report: primary brain tumors in the United States, 2000–2004. In: Edition Published by the Central Brain Tumor Registry of the United States 2008

Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018PubMedCrossRef

Fine HA, Dear KB, Loeffler JS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597PubMedCrossRef

Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMedCrossRef

http://www.accessdata.fda.gov/scripts/cder/onctools/druglist.cfm. Accessed 19 May 2009

Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRef

Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593PubMedCrossRef

10.

Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771PubMed

11.

Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRef

12.

Mirimanoff RO, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569PubMedCrossRef

13.

Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354PubMedCrossRef

14.

Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRef

15.

Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535PubMedCrossRef

16.

Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214PubMedCrossRef

17.

Glantz M, Chamberlain M, Liu Q et al (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266PubMedCrossRef

18.

Kimple RJ, Grabowski S, Papez M et al (2008) Glioblastoma in the elderly: radiation, chemoradiation, and supportive care. J Clin Oncol 26 (abstr 20738)

19.

Baker SD, Wirth M, Statkevich P et al (1999) Absorption, metabolism, and excretion of ¹⁴C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309–317PubMed

20.

Newlands ES, Stevens MF, Wedge SR et al (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35–61PubMedCrossRef

21.

Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295–2305PubMedCrossRef

22.

Marchesi F, Turriziani M, Tortorelli G et al (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56:275–287PubMedCrossRef

23.

Kanzawa T, Bedwell J, Kondo Y et al (2003) Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99:1047–1052PubMedCrossRef

24.

Roos WP, Batista LF, Naumann SC et al (2007) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O⁶-methylguanine. Oncogene 26:186–197PubMedCrossRef

25.

Ziegler DS, Kung AL, Kieran MW (2008) Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26:493–500PubMedCrossRef

26.

Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O⁶-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–1011PubMedCrossRef

27.

Balmaceda C, Peereboom D, Pannullo S et al (2008) Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112:1139–1146PubMedCrossRef

28.

Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol 11:69–79PubMedCrossRef

29.

Gasparini G (2001) Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2:733–740PubMedCrossRef

30.

Kim JT, Kim JS, Ko KW et al (2006) Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16:33–39PubMed

31.

Kurzen H, Schmitt S, Naher H, Mohler T (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14:515–522PubMedCrossRef

32.

Lee SM, Brada M, Stenning S, Thompson L, Gabe R (2008) A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12 ISRCTN83176944). Ann Oncol 19:viii2 (LBA 5)CrossRef

33.

Rabik CA, Njoku MC, Dolan ME (2006) Inactivation of O⁶-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 32:261–276PubMedCrossRef

34.

Turriziani M, Caporaso P, Bonmassar L et al (2006) O⁶-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O⁶-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res 53:317–323PubMedCrossRef

35.

Broniscer A, Gururangan S, MacDonald TJ et al (2007) Phase I trial of single-dose temozolomide and continuous administration of o⁶-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 13:6712–6718PubMedCrossRef

36.

Quinn JA, Desjardins A, Weingart J et al (2005) Phase I trial of temozolomide plus O⁶-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178–7187PubMedCrossRef

37.

Ranson M, Middleton MR, Bridgewater J et al (2006) Lomeguatrib, a potent inhibitor of O⁶-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 12:1577–1584PubMedCrossRef

38.

Khan OA, Ranson M, Michael M et al (2008) A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 98:1614–1618PubMedCrossRef

39.

Ranson M, Hersey P, Thompson D et al (2007) Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 25:2540–2545PubMedCrossRef

40.

Miknyoczki S, Chang H, Grobelny J et al (2007) The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 6:2290–2302PubMedCrossRef

41.

Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728–2737PubMedCrossRef

42.

Ganiere V, Christen G, Bally F et al (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi’s sarcoma after temozolomide. Nat Clin Pract Oncol 3:339–343 (quiz following 343)PubMedCrossRef

43.

FDA (2007) Temozolomide (marketed as Temodar): aplastic anemia. Drug Saf Newsl 1:7

44.

Doyle TJ, Mikkelsen T, Croteau D et al (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): report of a Phase II trial. J Clin Oncol 23 (abstract #1546)

45.

Jalali R, Singh P, Menon H, Gujral S (2007) Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. J Neurooncol 85:105–107PubMedCrossRef

46.

Morris B, Reiss U, Kasow K, Broniscer A (2008) Bone marrow transplantation (BMT) for aplastic anemia secondary to temozolomide therapy in a long-term survivor with glioblastomamultiforme (GBM). Neuro Oncol 10:396 (abstract CR2)

47.

Singhal N, Selva-Nayagam S, Brown MP (2007) Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment—case study and review of literature. J Neurooncol 85:229–230PubMedCrossRef

48.

Villano JL, Collins CA, Manasanch EE et al (2006) Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7:436–438PubMedCrossRef

49.

Gerber DE, Grossman SA, Zeltzman M et al (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9:47–52PubMedCrossRef

50.

Noronha V, Berliner N, Ballen KK et al (2006) Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol 8:280–283PubMedCrossRef

51.

Su YW, Chang MC, Chiang MF, Hsieh RK (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 71:315–318PubMedCrossRef

52.

Chamberlain MC, Glantz MJ, Chalmers L et al (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81–83PubMedCrossRef

53.

Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405–410PubMedCrossRef

54.

Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197PubMedCrossRef

55.

Ruben JD, Dally M, Bailey M et al (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65:499–508PubMed

56.

Giglio P, Gilbert MR (2003) Cerebral radiation necrosis. Neurologist 9:180–188PubMedCrossRef

57.

Gerstner ER, McNamara MB, Norden AD et al (2009) Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol [Epub ahead of print]

58.

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMed

59.

Quan D, Hackney DB, Pruitt AA et al (1999) Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. Neurology 53:211–213PubMed

60.

Ananthnarayan S, Bahng J, Roring J et al (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88:339–347PubMedCrossRef

61.

Hau P, Koch D, Hundsberger T et al (2007) Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68:688–690PubMedCrossRef

62.

Stupp R, Hottinger AF (2008) Management of malignant glioma—quo vadis? Onkologie 31:300–302PubMedCrossRef

Titel: Temozolomide in malignant gliomas: current use and future targets
verfasst von: J. Lee Villano
Tara E. Seery
Linda R. Bressler
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-1050-5

Springer Medizin

Temozolomide in malignant gliomas: current use and future targets

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine

Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells

Pro-apoptotic and cytostatic activity of naturally occurring cardenolides

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie